SCHEDULE 13G/A
0001072613-21-000065
0001666306
XXXXXXXX
LIVE
4
Common Stock par value $0.01 per share
03/31/2025
0001745999
Beam Therapeutics Inc.
07373V105
238 Main Street
Cambridge
MA
02142
Rule 13d-1(d)
ARCH Venture Fund IX, L.P.
DE
0.00
4540132.00
0.00
4540132.00
4540132.00
N
4.5
PN
ARCH Venture Fund IX Overage, L.P.
DE
0.00
4540132.00
0.00
4540132.00
4540132.00
N
4.5
PN
ARCH Venture Partners IX, L.P.
DE
0.00
4540132.00
0.00
4540132.00
4540132.00
N
4.5
PN
ARCH Venture Partners IX Overage, L.P.
DE
0.00
4540132.00
0.00
4540132.00
4540132.00
N
4.5
PN
ARCH Venture Partners IX, LLC
DE
0.00
4540132.00
0.00
4540132.00
4540132.00
N
4.5
OO
Keith Crandell
X1
17730.00
4540132.00
17730.00
4540132.00
4557862.00
N
4.5
IN
Clinton Bybee
X1
10498.00
4540132.00
10498.00
4540132.00
4550630.00
N
4.5
IN
Robert Nelsen
X1
60615.00
4540132.00
60615.00
4540132.00
4600747.00
N
4.6
IN
Beam Therapeutics Inc.
238 Main Street, Cambridge, MA 02142
ARCH Venture Fund IX, L.P. ("AVF IX"); ARCH Venture Partners IX, L.P. ("AVP IX LP"); ARCH Venture Partners IX, LLC ("AVP IX LLC"); ARCH Venture Fund IX Overage, L.P. ("AVF IX Overage"); ARCH Venture Partners IX Overage, L.P. ("AVP IX Overage GP") (collectively, the "Reporting Entities" and individually, each a "Reporting Entity"); and Keith Crandell ("Crandell"), Robert Nelsen ("Nelsen") and Clinton Bybee ("Bybee") (collectively, the "Managing Directors" and individually, each a "Managing Director"). The Reporting Entities and the Managing Directors collectively are referred to as the "Reporting Persons".
8755 W. Higgins Avenue, Suite 1025, Chicago, IL 60631
Each of AVF IX, AVP IX LP, AVF IX Overage and AVP IX Overage GP, are limited partnerships organized under the laws of the State of Delaware. AVP IX LLC is a limited liability company organized under the laws of the State of Delaware. Each Managing Director is a US citizen.
Y
N
Y
Y
Y
Y
Y
Y
ARCH Venture Fund IX, L.P.
ARCH Venture Partners IX, L.P.
its General Partner
05/15/2025
ARCH Venture Partners IX, LLC
its General Partner
05/15/2025
/s/ Mark McDonnell
* Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
05/15/2025
ARCH Venture Fund IX Overage, L.P.
ARCH Venture Partners IX Overage, L.P.
its General Partner
05/15/2025
ARCH Venture Partners IX, LLC
its General Partner
05/15/2025
/s/ Mark McDonnell
* Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
05/15/2025
ARCH Venture Partners IX, L.P.
ARCH Venture Partners IX, LLC
its General Partner
05/15/2025
/s/ Mark McDonnell
* Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
05/15/2025
ARCH Venture Partners IX Overage, L.P.
ARCH Venture Partners IX, LLC
its General Partner
05/15/2025
/s/ Mark McDonnell
* Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
05/15/2025
ARCH Venture Partners IX, LLC
/s/ Mark McDonnell
* Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
05/15/2025
Keith Crandell
/s/ Mark McDonnell
* Mark McDonnell, as Attorney-in-Fact for Keith Crandell
05/15/2025
Clinton Bybee
/s/ Mark McDonnell
* Mark McDonnell, as Attorney-in-Fact for Clinton Bybee
05/15/2025
Robert Nelsen
/s/ Mark McDonnell
* Mark McDonnell, as Attorney-in-Fact for Robert Nelsen
05/15/2025
* This Schedule 13G was executed by Mark McDonnell pursuant to a Power of Attorney filed as Exhibit 24 to the Form 3 relating to the beneficial ownership of shares of Beam Therapeutics, Inc. by the Reporting Persons filed with the Securities Exchange Commission on February 5, 2020 and incorporated herein in its entirety by reference.